Publication:
Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: expert panel recommendations

dc.contributor.coauthorGoker, Erdem
dc.contributor.coauthorAltwairgi, Abdullah
dc.contributor.coauthorAl-Omair, Ameen
dc.contributor.coauthorTfayli, Arafat
dc.contributor.coauthorBlack, Edward
dc.contributor.coauthorElsayed, Hany
dc.contributor.coauthorKoegelenberg, Coenraad
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T22:52:55Z
dc.date.issued2021
dc.description.abstractThe Middle East and Africa (MEA) region, a large geographical area, lies at the confluence of Asian, Caucasian and African races and comprises of a population with several distinct ethnicities. The course of management of non-small cell lung cancer (NSCLC) differs as per patients' performance status as well as stage of disease, requiring personalized therapy decisions. Although management of NSCLC has received a significant impetus in the form of molecularly targeted therapies and immune therapies in last few years, surgery remains gold standard for patients with early-stage disease. In case of unresectable disease, radiotherapy and chemotherapy are the primary management modalities. With newer therapies being approved for treatment of early stage disease, use of multi-disciplinary team (MDT) for comprehensive management of NSCLC is of prime importance. A group of experts with interest in thoracic oncology, deliberated and arrived at a consensus statement for the community oncologists treating patients with NSCLC in the MEA region. The deliberation was based on the review of the published evidence including literature and global and local guidelines, subject expertise of the participating panellists and experience in real-life management of patients with NSCLC. We present the proposed regional adaptations of international guidelines and recommends the MDT approach for management of NSCLC in MEA.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipAstraZeneca FZ LLC The preparation of this consensus statement and funding of the journal's article processing charges was supported by AstraZeneca FZ LLC. All authors had full access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
dc.description.volume158
dc.identifier.doi10.1016/j.lungcan.2021.05.025
dc.identifier.eissn1872-8332
dc.identifier.issn0169-5002
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85107695060
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2021.05.025
dc.identifier.urihttps://hdl.handle.net/20.500.14288/7104
dc.identifier.wos674402900010
dc.keywordsAssisted thoracoscopic surgery
dc.keywordsPositron-emission-tomography
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofLung Cancer
dc.subjectOncology
dc.subjectRespiratory system
dc.titleMulti-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: expert panel recommendations
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files